William Frank Iv Hulse Sells 81,446 Shares of MiMedx Group, Inc. (NASDAQ:MDXG) Stock

MiMedx Group, Inc. (NASDAQ:MDXG) CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.80, for a total transaction of $635,278.80. Following the transaction, the chief accounting officer now owns 494,774 shares in the company, valued at $3,859,237.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

MiMedx Group Stock Down 0.2 %

MDXG stock opened at $8.10 on Thursday. The company’s 50 day simple moving average is $8.51 and its 200-day simple moving average is $7.80. The firm has a market capitalization of $1.19 billion, a P/E ratio of 14.73 and a beta of 1.97. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. As a group, equities research analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a research note on Thursday, February 27th.

Hedge Funds Weigh In On MiMedx Group

Several large investors have recently bought and sold shares of MDXG. First Light Asset Management LLC acquired a new stake in shares of MiMedx Group during the 4th quarter valued at about $32,168,000. Norges Bank bought a new stake in MiMedx Group during the 4th quarter worth about $4,020,000. JPMorgan Chase & Co. lifted its holdings in MiMedx Group by 133.1% in the fourth quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company’s stock valued at $6,668,000 after buying an additional 395,739 shares during the period. Meros Investment Management LP bought a new position in shares of MiMedx Group in the 4th quarter worth $3,801,000. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in MiMedx Group by 484.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company’s stock worth $3,487,000 after buying an additional 300,433 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.